Keytruda beats Yervoy and edges ahead of Opdivo in first-line melanoma
This article was originally published in Scrip
Executive Summary
Merck & Co pivotal Phase III KEYNOTE-006 study investigating the PD-1 inhibitor Keytruda (pembrolizumab) compared to Bristol-Myers Squibb's Yervoy (ipilimumab) in the first-line treatment of patients with advanced melanoma has met its two primary endpoints of progression-free survival (PFS) and overall survival (OS). The trial will be stopped early based on the recommendation of an independent data monitoring committee.